Detection of Promoter DNA Methylation in Urine and Plasma Aids the Detection of Non–Small Cell Lung Cancer
Abstract
Low-dose CT screening can reduce lung cancer–related mortality. However, CT screening has an FDR of nearly 96%. We sought to assess whether urine samples can be a source for DNA methylation–based detection of non–small cell lung cancer (NSCLC).
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Aug 14, 2020
- Source ID
- 10.1158/1078-0432.ccr-19-2896
Entities
People
- Alicia Hulbert
- Anastasia Kottorou
- Apurva Mallisetty
- Bin Liu
- Cassandra Villani
- Chen Chen
- Christian Ascoli
- Enrico Benedetti
- Ignacio Jusue-torres
- James G. Herman
- Julio Ricarte Filho
- Klara Valyi-nagy
- Kristen Rodgers
- Kyla Holmes
- Lawrence E. Feldman
- Malcolm V. Brock
- Malek G. Massad
- Mary Pasquinelli
- Nicole Gastala
- Odile David
- Robert A. Winn
- Ron C Gaba
- Tomoaki Ito
- Tza-Huei Wang
Organizations
- Central South University
- Johns Hopkins School of Medicine
- Johns Hopkins University
- Juntendo University
- Loyola University Chicago
- United States Department of Defense
- University of Illinois College of Medicine
- University of Illinois at Chicago
- University of Patras
- University of Pittsburgh